BXT 1523

BXT 1523 is a preclinical **biosimilar monoclonal antibody** candidate from BioXpress Therapeutics developed against **CD52** as a biosimilar of alemtuzumab. It is intended for **multiple sclerosis** and **B-cell chronic lymphocytic leukemia**. Based on the provided pipeline and archived company materials, BXT 1523 is designed to bind CD52 on lymphocytes and deplete these cells through immune effector mechanisms including **antibody-dependent cellular cytotoxicity** and **complement-dependent cytotoxicity**, consistent with the reference product. Archived BioXpress materials indicate the program had entered **200 L bioreactor stage** with reported titers above **2.5 g/L**, supporting that the asset was in preclinical and manufacturing development rather than clinical-stage testing.

Other names

alemtuzumab biosimilar